Rifamycin SV MMX for the treatment of traveler's diarrhea. (13th August 2017)

• Record Type: Journal Article
• Authors: Lin, Shu-Wen; Lin, Chun-Jung; Yang, Jyh-Chin
• Is Part Of: Expert opinion on pharmacotherapy. Volume 18:Number 12(2017)
• Page Start: 1269
• Page End: 1277
• Publication Date: 2017-08-13
• Subjects: Infectious diarrhea -- non-absorbable antibiotics -- rifamycin SV MMX -- traveler's diarrhea; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2017.1353079
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Rifamycin SV MMX®, a non-absorbable rifamycin antibiotic formulated using the multi-matrix system, was designed to exhibit its pharmacological action on the distal small intestine and colon. Its clinical efficacy and safety profile in the treatment of traveler's diarrhea were evaluated in several clinical studies. Areas covered : This review summarizes all available evidence regarding clinical trials of the efficacy and safety profile of rifamycin SV MMX for the treatment of traveler's diarrhea. Expert opinion : Rifamycin SV MMX demonstrated an excellent pharmacokinetic profile with decreased systemic toxicity similar to rifaximin. In phase II and phase III clinical trials, concerns have been raised regarding the medicine's efficacy in terms of the time to last unformed stool and cure rate compared to current recommended antibiotics in the treatment of acute diarrhea caused by diarrheagenic Escherichia coli and invasive pathogens. The significance of the increase in MICs after the use of rifamycin SV MMX warrants further examination.